2-ethylbutane-1,2-diamine | 3815-29-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-ethylbutane-1,2-diamine
• 英文别名: 3-(Aminomethyl)pentan-3-amine
• CAS: 3815-29-0
• 化学式: C₆H₁₆N₂
• mdl: MFCD12190244
• 分子量: 116.206
• InChiKey: ZVZPXKGMHIJPET-UHFFFAOYSA-N

物化性质

• 沸点：
  69-70 °C(Press: 20 Torr)
• 密度：
  0.860±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  52
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-ethylbutane-1,2-diamine 在 吡啶 、 potassium tert-butylate 作用下， 以 苯 为溶剂， 反应 12.0h， 生成 (1S,5S,6R,7S)-1-Ethyl-7-methyl-6-phenyl-3,8-bis-(toluene-4-sulfonyl)-3,8-diaza-bicyclo[3.2.1]octan-6-ol
  参考文献：
  名称：

  Wessig, Pablo; Legart, Frank; Hoffmann, Berit, Liebigs Annalen der Chemie, 1991, # 10, p. 979 - 982

  摘要：

  DOI：
• 作为产物：
  描述：

  3-nitro-3-nitromethyl-pentane 在 溶剂黄146 、 铂 作用下， 生成 2-ethylbutane-1,2-diamine
  参考文献：
  名称：

  Porter; Wood, Journal of the Institute of Petroleum, 1951, vol. 37, p. 388,391

  摘要：

  DOI：

文献信息

• BENZOTHIOPHENE INHIBITORS OF RHO KINASE
  申请人：Kahraman Mehmet

  公开号：US20080021026A1

  公开（公告）日：2008-01-24

  The present invention relates to compounds and methods which may be useful as inhibitors of Rho kinase for the treatment or prevention of disease.

  本发明涉及化合物和方法，这些化合物和方法可能作为Rho激酶的抑制剂在治疗或预防疾病方面有用。
• Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20140128372A1

  公开（公告）日：2014-05-08

  The present application relates to novel substituted imidazo[1,2-a]pyridine-3-carboxamides, to processes for their preparation, to their use alone or in combinations for the treatment and/or prophylaxis of diseases and to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular for the treatment and/or prophylaxis of cardiovascular disorders.

  本申请涉及新型取代咪唑[1,2-a]吡啶-3-羧酰胺，其制备方法，单独或组合使用以治疗和/或预防疾病，以及用于制备治疗和/或预防疾病的药物，特别是用于治疗和/或预防心血管疾病。
• [EN] NOVEL BENZAMIDE COMPOUNDS FOR USE IN MCH RECEPTOR RELATED DISORDERS<br/>[FR] NOUVEAUX COMPOSES DE BENZAMIDE DESTINES A ETRE UTILISES DANS DES TROUBLES ASSOCIES AU RECEPTEUR DE MCH
  申请人：7TM PHARMA AS

  公开号：WO2004048319A1

  公开（公告）日：2004-06-10

  Novel compounds of Formula I which modulate MCH activity are disclosed, in which A is a linker, Ar, is an aryl or heteroaryl group; R1 is hydrogen or a lower alkoxy group; Q together with the carbonyl forms an amide group, which is further substituted with an amine group; R5 is hydrogen, halogen atoms, alkoxy groups, hydroxy, alkylamino groups, dialkylamino groups, hydroxylalkyl groups, carboxamido groups, acylamido groups, acyl groups, -CHO, nitrile, alkyl, alkenyl or alkynyl groups, -SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as -CH2CF3, -CF2CF3, -CF3, -OCF3, -SCF3; -SO2NH2, -SO2NHAlk, -SO2NAlk2, -SO2AIk; R8 is hydrogen, halogen atoms, alkyl, alkenyl or alkynyl groups, cycloalkyl groups, alkylcycloalkyl groups, alkoxy groups, dialkylamino groups, -CONHAIk, -CONAIk2, - NHCO-Alk, -CO-Alk, -SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as -CH2CF3, -CF2CF3, -CF3, -OCF3, -SCF3; X is H, F, Cl, Br, I, -SCH3, partially or fully fluorinated alkyl, alkoxy or thioalkoxy groups such as -CH2CF3, - CF2CF3, -CF3, -OCF3, -SCF3; OCH3 or lower alkyl or alkenyl group; and which are useful in the treatment or prevention of e.g. obesity, depression, diabetes, bulimia etc.

  公开了调节MCH活性的Formula I的新化合物，其中A是连接剂，Ar是芳基或杂环芳基；R1是氢或较低的烷氧基；Q与羰基一起形成酰胺基团，该基团进一步被氨基取代；R5是氢、卤素原子、烷氧基、羟基、烷基氨基基团、二烷基氨基基团、羟基烷基基团、羧酰胺基团、酰胺基团、酰基、-CHO、腈基、烷基、烯基或炔基、-SCH3、部分或完全氟代烷基、烷氧基或硫代烷氧基基团，如-CH2CF3、-CF2CF3、-CF3、-OCF3、-SCF3；-SO2NH2、-SO2NHAlk、-SO2NAlk2、-SO2AIk；R8是氢、卤素原子、烷基、烯基或炔基、环烷基、烷基环烷基、烷氧基、二烷基氨基基团、-CONHAIk、-CONAIk2、-NHCO-Alk、-CO-Alk、-SCH3、部分或完全氟代烷基、烷氧基或硫代烷氧基基团，如-CH2CF3、-CF2CF3、-CF3、-OCF3、-SCF3；X是H、F、Cl、Br、I、-SCH3、部分或完全氟代烷基、烷氧基或硫代烷氧基基团，如-CH2CF3、-CF2CF3、-CF3、-OCF3、-SCF3；OCH3或较低的烷基或烯基基团；这些化合物在治疗或预防肥胖、抑郁症、糖尿病、暴食症等方面是有用的。
• BENZIMIDAZOLE AND IMADAZOPYRIDINE CARBOXIMIDAMIDE COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160333009A1

  公开（公告）日：2016-11-17

  The present disclosure provides indoleamine 2,3-dioxygenase 1 (IDOL) inhibitors of Formula I: or pharmaceutically acceptable salts thereof, in which X, L, n, m, R 1 , R 2a , R 2b , R n , R m , and R t are as defined herein, as well as pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts thereof, and methods of using the same to treat conditions mediated by IDO1.

  本公开提供了式I的吲哌酮2,3-二氧化酶1（IDOL）抑制剂： 或其药学上可接受的盐，其中X、L、n、m、R 1 、R 2a 、R 2b 、R n 、R m 和R t 如本文所定义，以及包括式I化合物的药物组合物，或其药学上可接受的盐，并使用这些方法来治疗由IDO1介导的疾病。
• Carbamate compounds
  申请人：Fu Hong

  公开号：US20080214617A1

  公开（公告）日：2008-09-04

  Carbamate compounds having a structure represented by formula I (where R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are as defined herein) are useful as anti-tumor agents.

  具有由公式I表示的结构的氨基甲酸酯化合物（其中R1，R2，R3，R4，R5和R6如本文所定义）可用作抗肿瘤剂。